. Author manuscript; available in PMC: 2013 Oct 9.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Sep;15(9):1108–1115. doi: 10.1016/j.bbmt.2009.05.015

Table 1.

Characteristics of Patients and Donors Included in the Study Evaluating Lymphocyte Counts at day 30 after HSCT

HSCT with MUD	N = 5 , or median (range)
N = Diagnosis	102
AML	54
CML	38
MDS	10
Risk (low/high)	55/47
Age	37 (0-58)
Children (<18 years)	22 (22%)
Sex (M/F)	57/45
Donor age	36 (19-54)
Donor sex (M/F)	58/41
Female donor to Male recipient	12(12%)
Stem cell source (BM/PBSC)	44/58
NC dose (×10⁸/kg)	7.6 (0.6-63.8)
CD34 dose (×10⁶/kg)	6.8 (0.2-56.4)
GVHD prophylaxis
CsA + MTX	97
Other	5
Conditioning:
TBI-based	41
Bu-based	61
G-CSF post-HSCT	63 (62%)

HSCT indicates hematopoietic stem cell transplantation; MUD, matched unrelated donors; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; BM, bone marrow; PBSC, peripheral blood stem cells; NC, nucleated; CsA, cyclosporine; GVHD, graft-versus-host disease; MTX, methotrexate; Bu, busulfan.